Illexcor-Scientific Publications

Pipeline

Date	Publication
December 2024	A Novel Direct Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease – In Vivo Efficacy of ILX002 in Humanized Mice (Abdulmalik et al.)

Prior Publication

Date	Publication
May 2023	X-ray crystallography and sickle cell disease drug discovery-a tribute to Donald Abraham (Donkor et al.)
February 2023	Modulating hemoglobin allostery for treatment of sickle cell disease: current progress and intellectual property (Pagare et al.)
November 2020	VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditions (Abdlulmalik et al.)
October 2018	Rational modification of vanillin derivatives to stereospecifically destabilize sickle hemoglobin polymer formation (Deshpande et al.)
October 2011	Crystallographic analysis of human hemoglobin elucidates the structural basis of the potent and dual antisickling activity of pyridyl derivatives of vanillin (Abdulmalik et al.)
September 2008	Pyridyl derivatives of benzaldehyde as potential antisickling agents (Nnamani et al.)
February 2005	5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells (Abdulmalik et al.)
September 2004	Structural basis for the potent antisickling effect of a novel class of five-membered heterocyclic aldehydic compounds (Safo et al.)